Treatment of Superficial Basal Cell Carcinoma on Forehead with Efudex in 80-Year-Old Male
Apply Efudex (5-fluorouracil) 5% cream twice daily to the lesion for 3-6 weeks, potentially extending to 10-12 weeks until complete obliteration, though you should strongly consider imiquimod as a superior alternative for this patient. 1
Critical Clarification: Efudex vs. Imiquimod
First, note that Efudex is 5-fluorouracil (5-FU), not imiquimod as suggested in your expanded question. These are distinct topical agents with different efficacy profiles for superficial BCC.
FDA-Approved Efudex Regimen
For superficial basal cell carcinoma specifically:
- Use only the 5% strength formulation 1
- Apply twice daily in sufficient amount to cover the lesion 1
- Continue for minimum 3-6 weeks, but therapy may require 10-12 weeks before lesions are obliterated 1
- Complete healing may take 1-2 months after stopping treatment 1
- Apply with non-metal applicator or glove; wash hands immediately if using fingers 1
Expected response sequence: erythema → vesiculation → desquamation → erosion → re-epithelialization. Terminate when inflammatory response reaches erosion stage for actinic keratoses, but continue longer for BCC 1
Important Efficacy Consideration
Efudex has approximately 93% success rate for superficial BCC based on FDA label data 1, which is inferior to imiquimod's 80% tumor-free rate at 3 years 2. The 2018 AAD guidelines demonstrate that imiquimod is superior to 5-FU for superficial BCC, with 3-year tumor-free rates of 80% vs 68% respectively 2.
Why This Matters for Your 80-Year-Old Patient
For an elderly patient where surgery may be impractical or declined, topical therapy is appropriate 3. However:
- Imiquimod shows better long-term efficacy than 5-FU for superficial BCC 2
- Both are Level A recommendations with Level I evidence 2
- 5-FU may be preferred if the patient cannot tolerate the inflammatory response from imiquimod, which can be more intense 2
- Dose adjustments based on tolerance are reasonable - consider every-other-day treatment with treatment holidays if local reactions are severe 2
Critical Follow-Up Requirements
The patient must be followed for a reasonable period to determine if cure has been obtained 1. This is non-negotiable given the ~7% failure rate with 5-FU cream 1.
Common Pitfalls to Avoid
- Do not use Efudex for nodular or aggressive BCC subtypes - only superficial BCC 1
- Do not use on difficult anatomic sites where surgical success approaches 100% - surgery remains preferred for isolated, easily accessible lesions 1
- Expect significant local skin reactions (erythema, swelling, erosions, crusts) that may limit compliance 2
- Confirm diagnosis before treatment - this method has not been proven effective in other BCC types 1
Alternative Recommendation
Given the superior efficacy data, strongly consider switching to imiquimod 5% cream applied 5 times weekly for 6 weeks, which achieves 84-90% initial clearance rates 3, 4 and better long-term outcomes than 5-FU 2. For elderly patients specifically, imiquimod has shown 67% clinical remission at 10 weeks and 49.5% at 1 year in patients >65 years 5.